BrainStorm – Discover, Innovate, Deliver – Delivering on the Promise of Cellular Therapeutics Home

Discover. Innovate. Deliver.

BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.

LEARN MORE

Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn

OUR MISSION

BrainStorm is dedicated to defeating neurodegenerative diseases using an innovative, best-in-class, autologous cellular therapeutic technology platform, NurOwn^®.

NUROWN® TECHNOLOGY PLATFORM

Play Video

BrainStorm’s autologous MSC-NTF cell therapy is investigational and not FDA approved.

Defining a new class of autologous cellular therapeutics

Grounded in breakthrough scientific innovation and focused on unmet medical need, BrainStorm is building a best-in-class platform, NurOwn^®, for production of commercial-ready MSC-NTF cells to treat highly debilitating neurodegenerative diseases that currently have limited treatment options.

WHAT WE DO

BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is a clinical-stage, biotechnology company focused on the development of best-in-class autologous cellular therapeutics for the treatment of highly debilitating neurodegenerative diseases.